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EZH2 Modulates the DNA Methylome and Controls T Cell
Adhesion Through Junctional Adhesion Molecule A in
Lupus Patients
Pei-Suen Tsou, Patrick Coit, Nathan C. Kilian, and Amr H. Sawalha
Objective. EZH2 is an epigenetic regulator that
mediates H3K27 trimethylation (H3K27me3) and mod-
ulates DNA methylation. The aim of this study was to
characterize the role of EZH2 in CD4+ T cells in the
pathogenesis of systemic lupus erythematosus.
Methods. EZH2 expression levels were deter-
mined in CD4+ T cells isolated from lupus patients and
healthy controls. The epigenetic effects of EZH2 overex-
pression in CD4+ T cells were evaluated using a genome-
wide DNA methylation approach. Gene expression
profiles and microRNAs (miRNAs) were assessed by
quantitative polymerase chain reaction, while protein
expression was examined by Western blotting. A cell
adhesion assay was used to assess adhesion of CD4+ T
cells to human microvascular endothelial cells.
Results. EZH2 and H3K27me3 levels were in-
creased in CD4+ T cells from lupus patients compared to
healthy controls. T cell production of EZH2 was down-
regulated in the presence of miR-26a and miR-101, and
levels of both miRNAs were reduced in lupus CD4+ T
cells. Overexpression of EZH2 induced in CD4+ T cells
resulted in significant DNA methylation changes. Genes
involved in leukocyte adhesion and migration, including
F11R (which encodes junctional adhesion molecule A
[JAM-A]), became hypomethylated in CD4+ T cells when
EZH2 was overexpressed. Overexpression of EZH2
resulted in increases in JAM-A expression and CD4+ T
cell adhesion. Preincubation of EZH2-transfected CD4+
Tcells with neutralizing antibodies against JAM-A signif-
icantly blunted cell adhesion. Similarly, CD4+ T cells
from lupus patients overexpressed JAM-A and adhered
significantly more to endothelial cells than to T cells from
healthy controls. Blocking JAM-A or EZH2 significantly
reduced the capacity of lupus CD4+ T cells to adhere to
endothelial cells.
Conclusion. The results of this study identify a
novel role of EZH2 in T cell adhesion mediated by epige-
netic remodeling and up-regulation of JAM-A. Blockade
of EZH2 or JAM-A might have therapeutic potential by
acting to reduce T cell adhesion, migration, and extrava-
sation in patients with lupus.
Systemic lupus erythematosus (SLE) is a chronic,
relapsing autoimmune disease that is characterized by
autoantibody production and a wide variety of clinical
manifestations along with multiple organ involvement.
Although the underlying cause of lupus is largely
unknown, substantial research has pointed to the involve-
ment of both genetic and epigenetic mechanisms (1,2). In
particular, DNA methylation, an epigenetic marker that is
heritable, stable, and reversible, has been shown to play
crucial roles in mediating the pathogenesis of lupus (3,4).
It not only affects gene expression patterns and the func-
tion of genes in lupus CD4+ Tcells (5,6), but also primes
interferon-regulated genes in lupus-naive CD4+ Tcells to
be epigenetically poised to respond to interferon upon
activation (4). CD4+ T cells from lupus patients with
active disease show more pronounced defects in DNA
methylation as compared to those from lupus patients
with inactive disease (7–9).
In a recent study by our group, the findings sug-
gested that with lupus flares, naive CD4+ Tcells undergo
a shift in DNA methylation to favor T cell activation.
Furthermore, this shift poises CD4+ Tcells for Th2, Th17,
and follicular helper Tcell responses (10). Bioinformatics
and literature-mining analyses have demonstrated a sig-
nificant enrichment of EZH2 binding sites in loci that
exhibit progressive increases in DNA methylation levels
in conjunction with greater lupus disease activity,
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suggesting that EZH2 has a role in the progression of
lupus. In addition, levels of 2 microRNAs (miRNAs) that
target and regulate EZH2, miR-101 and miR-26a, in naive
CD4+ Tcells from lupus patients were found to be nega-
tively correlated with the extent of lupus disease activity.
In this study, we set forth to further evaluate the
role of EZH2 in CD4+ T cells from patients with SLE.
We sought to determine the expression of EZH2, along
with the 2 miRNAs that control EZH2 expression, in
naive CD4+ T cells from lupus patients in comparison
to healthy controls. Through examination of the
changes occurring in the genome-wide DNA methyla-
tion status after overexpression of EZH2 in naive
CD4+ T cells, we discovered a novel functional role of
EZH2 in CD4+ T cells that has potential therapeutic
implications in the management of lupus.
PATIENTS AND METHODS
Patients and controls. All patients included in our study
met the American College of Rheumatology revised criteria for
the classification of SLE (11). Patients (n = 57; all female, medi-
an age 42 years [range 19–60 years], mean  SD age 40  11
years) and healthy controls (n = 40; all female, median age 44
years [range 20–63 years], mean  SD age 44  11 years) were
recruited from the University of Michigan Rheumatology Clin-
ics. The SLE Disease Activity Index (SLEDAI) scores (12) in
the patients ranged from 0 to 12, with a mean score of 3 and
median score of 2. All subjects included in this study provided
written informed consent. All procedures in this study were
reviewed and approved by the Institutional Review Board of the
University of Michigan.
Cell isolation and culture. Naive CD4+ Tcells were iso-
lated from the whole blood of subjects using a naive CD4+
T cell isolation kit (Miltenyi Biotec), which allows for the indi-
rect isolation of untouched naive CD4+ T cells, as previously
described (10). In some experiments, isolated naive CD4+
T cells were left unstimulated or were stimulated overnight
with anti-CD3 antibodies (10 lg/ml, precoated on plates) and
anti-CD28 antibodies (2.5 lg/ml). Human microvascular
endothelial cells (HMVECs) were grown in endothelial basal
medium 2 (EBM-2) with growth factors (Lonza). Cells between
passages 3 and 9 were used in the experiments.
Overexpression experiments. Overexpression of EZH2
in naive CD4+ T cells was performed using an Amaxa
4D-Nucleofactor system (Lonza). After isolation and purifica-
tion, naive CD4+ Tcells from healthy subjects were transfected
with 0.1 lg of EZH2, or pCMV6-XL5 as a control vector (both
from OriGene), and cultured in RPMI medium supplemented
with 10% fetal bovine serum (FBS) and 2 mM L-glutamine.
After 5 hours of transfection, the culture medium was changed
to remove the transfection reagent, and the cells were stimu-
lated overnight with anti-CD3 and anti-CD28 antibodies. The
cells were cultured for an additional 48 hours before protein
and RNA were collected. In addition, DNA was extracted for
the DNA methylation assessment (as described below).
Similar procedures were carried out for the miRNA
overexpression experiments, using the Amaxa 4D-Nucleofactor
system. Naive CD4+ T cells from healthy subjects were trans-
fected with 500 nM of miR-26a or 500 nM of miR-101 (mirVana
miRNA mimic; Thermo Fisher Scientific) and stimulated over-
night. RNA was collected on day 3 posttransfection. The cell
survival rate for the miRNA-transfected cells was ~55%.
Extraction of messenger RNA (mRNA) and quantita-
tive reverse transcription–polymerase chain reaction (qRT-
PCR). Total RNA from the cells was isolated using a Direct-zol
RNA MiniPrep kit (Zymo Research). Preparation of comple-
mentary DNA (cDNA) was done using a Verso cDNA synthesis
kit (Thermo Fisher Scientific). Primers for human EZH2, the
DNA methyltransferase genes DNMT1 and DNMT3A, the
methyl-CpG binding protein gene MeCP2, and b-actin, along
with Power SYBR Green PCR Master Mix (Applied Biosys-
tems), were used for qRT-PCR, which was run using a ViiA 7 real-
time PCR system. Primer sequences are as follows: for DNMT1,
forward CGACTACATCAAAGGCAGCAACCTG and reverse
TGGAGTGGACTTGTGGGTGTTCTC; for DNMT3A, forward
CGAGTCCAACCCTGTGATGATTG and reverse CGTGGTCT-
TTGCCCTGCTTTATG; for b-actin, forward GTCAGGCAGCT-
CGTAGCTCTand reverse GCCATGTACGTTGCTATCCA. The
EZH2 primers were KiCqStart SYBR Green primers (Sigma),
and theMeCP2 primers were purchased from Qiagen (QuantiTect
Primer Assays). Expression of miRNAs was analyzed using
TaqMan Advanced miRNA assays (Thermo Fisher Scientific).
Western blotting. Cell lysates were prepared from
CD4+ Tcells obtained from lupus patients and healthy subjects.
Proteins were separated by sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis, and then electroblotted onto nitro-
cellulose membranes. EZH2, junctional adhesion molecule A
(JAM-A), and trimethylated H3K27 (H3K27me3) were
detected using anti-human EZH2 antibodies (Cell Signaling
Technology), anti–JAM-A antibodies (Santa Cruz Biotechnol-
ogy), and anti-H3K27me3 antibodies (Cell Signaling), while b-
actin and histone H3 were used as loading controls (anti–b-actin
antibodies from Sigma-Aldrich; anti-H3 antibodies from Cell
Signaling Technology). Images were visualized using an Omega
Lum C imaging system (Gel Company), and quantification of
the bands was performed using GelQuant.NET (BiochemLab
Solutions).
DNA methylation assessment and analysis. Naive
CD4+ Tcells from 4 healthy subjects, left unstimulated or stim-
ulated overnight, were transfected with an EZH2 overexpres-
sion vector or a control vector. Genomic DNA was then
isolated from the cells and bisulfite converted using an EZ
DNA Methylation kit (Zymo Research). The genome-wide
DNA methylation status of each sample was evaluated using an
Illumina Infinium Methylation EPIC BeadChip array. An Illu-
mina GenomeStudio platform was used to analyze the methyla-
tion data, as previously described (4). The average level of
DNA methylation (b) on each CpG site was compared between
the control and EZH2-overexpressing CD4+ T cells. Differen-
tially methylated CpG sites were defined as those with a differ-
ential methylation score of ≥|22| (equivalent to a P value of less
than 0.05, after adjustment for multiple testing) and a mean
methylation difference of >10% between the 2 groups. Differ-
entially methylated genes were analyzed for Gene Ontology
(GO), network, and pathway enrichments using the DAVID
Bioinformatics Database (version 6.7) (13,14).
In vitro cell adhesion assay. An adhesion assay to assess
the capacity of CD4+ Tcells to adhere to HMVECs was carried
out as previously described (15), with slight modification.
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HMVECs were grown in 96-well plates and stimulated with
tumor necrosis factor (25 ng/ml) in EBM-2 medium containing
0.1% FBS. Overexpression of EZH2 was induced in naive CD4+
T cells in the same manner as described above. The stimulated
EZH2-overexpressing CD4+ T cells (50,000 cells/well in 100 ll
RPMI medium) were labeled with calcein AM cell-permeant
dye (5 lM; Invitrogen), in the presence or absence of neutraliz-
ing antibodies to JAM-A (50 lg/ml; BioLegend) or an isotype
control (mouse IgG1j; BioLegend). The fluorescence-tagged T
cells were washed with phosphate buffered saline (PBS) twice,
and then added to HMVEC cultures and incubated for 30 min-
utes. Nonadherent Tcells were washed off, and the fluorescence
intensity was measured at an absorbance of 485/528 nm using a
Synergy HT fluorescence plate reader (BioTek Instruments).
We also examined the capacity of lupus CD4+ T cells
to adhere to HMVECs. Naive CD4+ T cells were isolated
from lupus patients and stimulated overnight. The cells were
cultured for an additional 2 days before they were assayed for
adhesion capacity in the same manner as described above.
The effect of JAM-A in lupus CD4+ T cells was also evalu-
ated using neutralizing antibodies to JAM-A. After culturing
for 3 days, stimulated CD4+ T cells from lupus patients were
washed in PBS and labeled with calcein AM, in the presence
or absence of neutralizing antibodies to JAM-A or isotype
control. After washing with PBS, the fluorescence-tagged T
cells were subjected to adhesion assays, as described above.
To determine whether inhibition of EZH2 would affect
T cell adhesion, naive CD4+ T cells from lupus patients were
stimulated overnight in the presence of DZNep (5 lM, dissolved
in PBS; Cayman Chemical), and 1 day thereafter, the medium
was changed to remove the stimulants. The T cells were treated
with DZNep for an additional 2 days, and the cells were washed
with PBS twice and then assayed for adhesion. The cell survival
rate of the DZNep-treated cells was ~77%.
Meanwhile, an aliquot of cells was lysed and saved for
Western blotting to check the expression of EZH2, JAM-A, and
H3K27me3 after DZNep treatment. To visualize Tcell adhesion
to HMVECs, dye-tagged stimulated CD4+ T cells from healthy
controls, stimulated CD4+ T cells from lupus patients, and
DZNep-treated CD4+ T cells from lupus patients were plated
on HMVECs that were labeled with the red fluorescence dye
PKH26 (Sigma). Images of the cells were obtained using an
EVOS FL cell imaging system (Thermo Fisher Scientific). In
order to evaluate the effect of EZH2 on cell adhesion,
Figure 1. Expression of EZH2, trimethylated H3K27 (H3K27me3), and microRNAs (miRNAs) in CD4+ T cells isolated from healthy controls
and patients with systemic lupus erythematosus (SLE). A, Protein levels of EZH2 were assessed by Western blotting (WB) (top) and quantified
(bottom) relative to the expression of b-actin in naive CD4+ T cells from lupus patients compared to healthy controls, with no stimulation (NS) or
after overnight stimulation (Stim) with anti-CD3 and anti-CD28 antibodies. B, Expression of EZH2 mRNA was determined in naive CD4+ T cells
from lupus patients compared to healthy controls, after overnight stimulation. C, Levels of H3K27me3 were assessed by Western blotting (top)
and quantified (bottom) relative to the expression of histone H3 in naive CD4+ T cells from lupus patients compared to healthy controls, after
overnight stimulation. D and E, Levels of miR-26a (D) and miR-101 (E) were determined in lupus and healthy control naive CD4+ T cells, after
overnight stimulation. Bars show the mean  SD in each group.
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experiments with GSK126, which inhibits the catalytic activity of
EZH2, but not the expression of EZH2 (16), were performed.
The procedures used were similar to those used in the experi-
ments with DZNep. The final concentration of GSK126 (Cay-
man Chemical) was 5 lM, and DMSO was used as the vehicle
control.
Statistical analysis. Results are expressed as the mean
 SD. To determine differences between groups, the Mann-
Whitney U test was performed, and data were analyzed using
GraphPad Prism (version 6; GraphPad Software). One-way anal-
ysis of variance (ANOVA) followed by Sidak’s post hoc test was
used to compare differences in EZH2-overexpressing or
miRNA-overexpressing cells, and two-way ANOVA with Tukey’s
post hoc test was used to identify differences in EZH2 expres-
sion between healthy control and lupus T cells, with or without
overnight stimulation. To compare the expression changes
before and after EZH2 overexpression, Wilcoxon’s test was per-
formed. P values less than 0.05 were considered significant.
RESULTS
Expression of EZH2, H3K27me3, and miRNA in
lupus patients. We first examined the expression of
EZH2 in CD4+ Tcells isolated from healthy controls and
lupus patients. At the protein level, when the cells were
stimulated, an increase in the levels of EZH2 was
observed in lupus Tcells but not in healthy control Tcells
(Figure 1A). In addition, stimulation of the T cells led to
a significant increase in EZH2 expression in lupus T cells
compared to healthy control T cells. EZH2 mRNA levels
were also observed to be significantly increased in CD4+
T cells from lupus patients compared to CD4+ T cells
from healthy controls (Figure 1B).
Since EZH2 trimethylates the histone H3K27,
we measured this histone using Western blotting. As
shown in Figure 1C, there was a significant increase in
H3K27me3 levels in CD4+ T cells from lupus patients
compared to those from healthy controls, consistent
with the observed increase in EZH2 levels in lupus
samples.
Since both miR-26a and miR-101 control EZH2
expression (16), we then examined the expression of
these miRNAs in healthy control and lupus naive
CD4+ T cells that were stimulated overnight. The levels
of both miR-26a and miR-101 were significantly
reduced in lupus T cells compared to healthy control T
cells (Figures 1D and E). The reduction in expression
of these miRNAs in lupus T cells is consistent with,
and could potentially explain, the higher levels of
EZH2 observed in lupus patients compared to healthy
controls.
Control of expression of EZH2 by miR-26a and
miR-101 in naive CD4+ T cells. To confirm the inhibi-
tory effects of miR-26a and miR-101 on EZH2 expres-
sion in naive CD4+ T cells, we overexpressed either
miR-26a or miR-101 in naive CD4+ Tcells isolated from
healthy controls and stimulated the cells in vitro.
Successful overexpression of miR-26a (Figure 2A) and
Figure 2. Effects of overexpression of microRNAs (miRNAs) miR-
26a and miR-101 on the levels of EZH2 mRNA in stimulated CD4+
T cells. A and B, Naive CD4+ T cells isolated from healthy subjects
were transfected with 500 nM miR-26a, miR-101, or control miRNA
and stimulated overnight. On day 3 posttransfection, overexpression
of miR-26a (A) and miR101 (B) was confirmed using a TaqMan
Advanced miRNA assay. C, EZH2 mRNA levels were determined in
miR-26a–overexpressing and miR-101–overexpressing CD4+ T cells in
comparison to control-transfected cells. Values are the mean  SD.
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miR-101 (Figure 2B) was first confirmed using a
TaqMan Advanced miRNA assay. Indeed, both overex-
pression of miR-26a and overexpression of miR-101
decreased the expression of EZH2 mRNA in stimulated
CD4+ Tcells (Figure 2C).
We also overexpressed both miR-26a and miR-101
simultaneously, hypothesizing that the 2 miRNAs might
act synergistically to suppress EZH2 expression. Surpris-
ingly, miR-101 appeared to negatively impact miR-26a
expression, since simultaneous overexpression of both
miRNAs in CD4+ Tcells led to significantly lower miR-26a
levels compared to the levels in cells overexpressing miR-
26a alone (mean  SD fold increase in miR-26a levels 40.1
 26.4 in miR-26a–overexpressing Tcells versus 13.9  8.0
in miR-26a and miR-101–overexpressing T cells [n = 6
samples per group]; P < 0.05).
Effects of overexpression of EZH2 on genome-
wide DNAmethylation in naive CD4+ Tcells. To examine
the effect of EZH2 on CD4+ T cells, EZH2 was overex-
pressed in naive CD4+ Tcells isolated from healthy sub-
jects. Successful overexpression of EZH2 was confirmed
at both the mRNA level (Figure 3A) and protein level
(Figure 3B). Overexpression of EZH2 also led to
increased H3K27me3 levels (Figure 3B).
We then evaluated DNA methylation changes in
control-transfected or EZH2-overexpressing naive CD4+
T cells, with or without overnight stimulation. When the
cells were left unstimulated, we identified 19 differentially
methylated CpG sites in EZH2-overexpressing naive
CD4+ Tcells (see Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40338/abstract), of which 8 were
hypermethylated and 11 were hypomethylated in compar-
ison to control-transfected CD4+ Tcells, corresponding to
5 differentially methylated unique genes and 7 differen-
tially methylated unique genes, respectively. When the
Figure 3. Effects of EZH2 overexpression in stimulated CD4+ T cells on the expression of junctional adhesion molecule A (JAM-A) and enzymes
and proteins involved in DNA methylation. A, Overexpression of EZH2 mRNA in EZH2 vector–transfected CD4+ T cells, in comparison to con-
trol vector–transfected CD4+ T cells, was confirmed by quantitative polymerase chain reaction. B, Western blots (WB) (representative results from
1 of 3 experiments) show that EZH2 overexpression was paralleled by increased expression of JAM-A and trimethylated H3K27 (H3K27me3) in
CD4+ T cells; b-actin and histone H3 were used as loading controls. C, Western blots show that JAM-A was overexpressed in stimulated naive
CD4+ T cells from patients with systemic lupus erythematosus (SLE) compared to healthy controls. D–F, Expression of the methyl-CpG binding
protein gene MeCP2 (D) and DNA methyltransferase genes DNMT1 (E) and DNMT3A (F) was compared between EZH2-overexpressing CD4+ T
cells and control cells. Results are the mean  SD (n = 14 samples per group).
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cells were stimulated overnight, a total of 324 differ-
entially methylated CpG sites in EZH2-overexpressing
CD4+ Tcells were identified (see Supplementary Table 1).
Among them, 156 were hypomethylated and 168 were
hypermethylated as compared to control-transfected cells.
A total of 264 differentially methylated genes were identi-
fied in EZH2-transfected CD4+ Tcells following stimula-
tion, with ~50% of them being hypomethylated. The top
hypomethylated gene in both unstimulated and stimulated
EZH2-overexpressing CD4+ T cells was EZH2 (see Sup-
plementary Table 1). These findings are a reflection of the
overexpression of EZH2 in our experiments, since the 2
hypomethylated CpG sites in EZH2 are located in the
gene body, suggesting that these are from the transfected
EZH2 vector. In addition to EZH2, IL34 (gene for
interleukin-34) was the only hypomethylated gene that
was common between the unstimulated and stimulated
EZH2-overexpressing CD4+ Tcells.
We next used the DAVID database for gene func-
tion enrichment analysis, to group the differentially
methylated genes into GO and biologic pathways. The
results showing top pathways and GOs enriched among
the genes that were significantly hypomethylated with
EZH2 overexpression are summarized in Table 1. “Cell
adhesion molecules” and “leukocyte migration” appeared
to be enriched in both the functional annotation pathway
and GO analyses. The genes that overlapped in both
terms included F11R, SELP, and SELPLG. F11R encodes
JAM-A, while SELP codes for p-selectin and SELPLG
codes for p-selectin glycoprotein ligand 1 (PSGL1). Since
p-selectin is predominantly expressed on endothelial cells
to mediate leukocyte adhesion through interaction with
Figure 4. Effects of EZH2 on lymphocyte adhesion. A and B, Stimulated CD4+ T cells overexpressing EZH2 or transfected with a control vector
were assessed for their ability to adhere to human microvascular endothelial cells (HMVECs) overall (A) and in the presence of neutralizing anti-
bodies (ab) to junctional adhesion molecule A (JAM-A) (B). C and D, Naive CD4+ T cells from patients with systemic lupus erythematosus (SLE)
and healthy controls were stimulated overnight and assessed for adhesion to HMVECs overall (C) and in the presence of anti–JAM-A (D). In
these experiments, IgG was used as an isotype control. E–G, Effects of pretreatment with the EZH2 inhibitor DZNep for 3 days, using phosphate
buffered saline (PBS) as a control, were assessed in stimulated CD4+ T cells isolated from lupus patients, in relation to changes in EZH2 mRNA
levels (E), protein levels of EZH2, JAM-A, and trimethylated H3K27 (H3K27me3) (F), and adhesion of the cells to HMVECs (G). H, Stimulated
CD4+ T cells isolated from a lupus patient (green) were assessed for their ability to adhere to HMVECs (red). Representative immunofluores-
cence images show adhesion assay results in cells from a healthy control subject and a lupus patient in the absence or presence of treatment with
DZNep. I, Effects of pretreatment with GSK126 for 3 days, using DMSO as a control, were assessed in stimulated CD4+ T cells isolated from
lupus patients, in relation to adhesion of the cells to HMVECs. Values are the mean  SD. Adhesion is measured as the intensity of fluorescence
(FLU). WB = Western blotting.
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PSGL1 (17), we focused our subsequent studies on F11R
and SELPLG in naive CD4+ Tcells.
Interestingly, SELPLG was hypermethylated in
unstimulated EZH2-overexpressing CD4+ Tcells, whereas
it was hypomethylated after stimulation with anti-CD3
and anti-CD28 antibodies. However, the expression of
PSGL1 remained unaltered with EZH2 overexpression in
stimulated CD4+ T cells (data not shown), while JAM-A
expression was significantly increased (Figure 3B). In
addition, JAM-A was also significantly up-regulated in
stimulated CD4+ Tcells from lupus patients compared to
those from healthy controls (Figure 3C).
Since EZH2 overexpression led to significant
changes in the DNA methylome in CD4+ T cells, we
examined whether EZH2 affects the expression of
enzymes and proteins that are directly involved in DNA
methylation. Indeed, in EZH2-overexpressing cells, the
expression levels of both MeCP2 mRNA (Figure 3D)
and DNMT3A mRNA (Figure 3F) were significantly
lower than those in control-transfected T cells, while
DNMT1 mRNA expression was not affected by EZH2
overexpression (Figure 3E).
Mediation of CD4+ T cell adhesion to endothelial
cells by EZH2 in patients with lupus. Since our pathway
and GO analyses pointed to the involvement of EZH2 in
leukocyte adhesion and migration (Table 1), we examined
whether overexpression of EZH2 affects cell adhesion of
stimulated CD4+ T cells to HMVECs. As shown in
Figure 4A, overexpression of EZH2 increased the adhe-
sion of Tcells to HMVECs.
Since JAM-A was hypomethylated and up-regu-
lated in EZH2-overexpressing naive CD4+ T cells (Fig-
ure 3B), we examined whether the increased adhesion
capacity of these cells was mediated by JAM-A. When
JAM-A was blocked with neutralizing antibodies, the
increased adhesion of EZH2-overexpressing CD4+ T
cells to HMVECs was normalized (Figure 4B). Since we
showed that EZH2 is overexpressed in lupus naive CD4+
T cells following stimulation (Figures 1A and B), we
hypothesized that these cells would behave in a manner
similar to EZH2-overexpressing CD4+ Tcells in terms of
cell adhesion. Indeed, lupus CD4+ T cells showed
enhanced cell adhesion to HMVECs when compared to
healthy control CD4+ Tcells (Figure 4C).
Since we also observed increased JAM-A expres-
sion in lupus CD4+ T cells (Figure 3C), we examined
the effects of blocking the expression of JAM-A. Cell
adhesion of lupus CD4+ T cells was significantly
reduced by blockade of JAM-A (Figure 4D). These
results suggest that EZH2 mediates increased T cell
adhesion in lupus via the overexpression of JAM-A.
To determine whether inhibition of EZH2 can nor-
malize T cell adhesion in lupus, we used DZNep, an
EZH2 inhibitor. DZNep treatment decreased the expres-
sion of EZH2 and JAM-A, and also decreased the levels
of H3K27me3 (Figures 4E and F). Furthermore, as
shown in Figures 4G and H, treating stimulated lupus
CD4+ Tcells with DZNep significantly reduced their abil-
ity to adhere to HMVECs.
To validate the effect of DZNep on T cell adhe-
sion and determine whether this effect is dependent on
H3K27me3, we used GSK126, which inhibits the enzy-
matic activity of EZH2, but not the expression of EZH2.
Similar to what we observed in DZNep-treated cells,
treatment of the cells with GSK126 led to a significant
reduction in lupus T cell adhesion to HMVECs (Fig-
ure 4I), suggesting that EZH2-mediated T cell adhesion
in lupus is dependent on the catalytic activity of EZH2.
DISCUSSION
In this study, we focused on the expression and
function of EZH2 in lupus CD4+ Tcells, and identified a
novel role of EZH2 in T cell adhesion. We previously
demonstrated that this epigenetic modulator might be
mediating proinflammatory epigenetic reprogramming in
naive CD4+ Tcells in lupus patients when increases in dis-
ease activity occur (10). Herein we demonstrate increased
expression of EZH2 and H3K27me3 in naive CD4+ T
cells obtained from lupus patients compared to those
from healthy controls following in vitro stimulation. In
addition, both miR-26a and miR-101, which target
EZH2, were significantly down-regulated in stimulated
lupus naive CD4+ T cells. Overexpression of EZH2 in
naive CD4+ T cells from healthy individuals resulted in
genome-wide DNA methylation changes, and functional
enrichment analysis of the affected genes led us to exam-
ine the role of EZH2 in Tcell adhesion. We demonstrated
that in vitro–stimulated CD4+ T cells, either those iso-
lated from lupus patients or EZH2-overexpressing cells
from healthy subjects, showed increased T cell adhesion
to HMVECs as compared to their corresponding con-
trols. This was mediated through increased expression of
JAM-A in both cases. Blockade of EZH2 by DZNep and
GSK126 efficiently blunted lupus T cell adhesion to
HMVECs, suggesting that blocking EZH2 may be a ther-
apeutic option for lupus.
As the catalytic component of a multiprotein com-
plex, polycomb repressive complex 2, that catalyzes
H3K27me3, EZH2 is involved in chromatin compaction
and gene repression. When phosphorylated, it acts as a
transcriptional activator instead, and this function might
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be independent of its methyltransferase activity (18).
Although EZH2 preferentially targets histones, it has been
shown to serve as a recruitment platform for DNAmethyl-
transferases to directly control DNA methylation and
exert their gene repression activity concurrently (19,20). In
this study, we showed that EZH2 overexpression led to
genome-wide changes in DNA methylation. In addition to
genes involved in cell adhesion and leukocyte migration,
as highlighted in this study, we also discovered genes that
showed differential methylation changes after EZH2 over-
expression; these genes are involved in gene transcription
(such as EMX1 and TAF1), ubiquitination processes
(BTRC and NEDD4L), as well as immune responses
(CTLA4, IL34, HLA-E, OAS2, and PGLYRP4) (Table 1;
see also Supplementary Table 1, http://onlinelibrary.wiley.c
om/doi/10.1002/art.40338/abstract). These findings suggest
that EZH2 is involved in various cellular and physiologic
processes crucial for Tcell survival and function.
The exact mechanism of how EZH2 alters the
methylome in naive CD4+ T cells is not clear. However,
we show that overexpression of EZH2 leads to repressed
expression of both DNMT3A and MeCP2 in naive CD4+
Tcells, which might result in reduced locus-specific DNA
methylation or increased chromatin accessibility. In addi-
tion, the methylcytosine dioxygenase TET1 was hyperme-
thylated in EZH2-overexpressing CD4+ T cells (see
Supplementary Table 1). The bivalent repressive/activat-
ing effect of EZH2 could explain the similar numbers of
differentially hypermethylated CpG sites and differen-
tially hypomethylated CpG sites (168 and 156, respec-
tively) after EZH2 overexpression in naive CD4+ Tcells.
Although the function of EZH2 in Tcell differenti-
ation remains controversial, it is clear that this pleiotropic
enzyme plays a key role in maintaining Tcell homeostasis
(16,21–23). Recently, a new function of EZH2 has been
revealed. In dendritic cells and neutrophils, EZH2 was
shown to control cell adhesion and migration through
direct methylation of talin, which directly links integrins
to the actin cytoskeleton (24). In the current study, we
also showed that EZH2 mediates cell adhesion, albeit in a
different cell type and with a different mechanism. Our
data suggest that EZH2 promotes T cell adhesion to
endothelial cells via, at least in part, demethylation and
up-regulation of JAM-A. This was found to be true both
in naive CD4+ T cells overexpressing EZH2 and in naive
CD4+ T cells from lupus patients, in which expression of
EZH2 is increased.
Despite our findings, the exact role of EZH2 in
lupus T cells is yet to be fully understood. The role of
EZH2 in T cell differentiation and invasiveness is poten-
tially crucial for lupus pathogenesis. EZH2 expression
was previously examined in total CD4+ Tcells from lupus
patients and healthy controls (25). Those investigators
showed that EZH2 mRNA levels were significantly down-
regulated in total CD4+ T cells from lupus patients with
active disease as well as those from lupus patients with
inactive disease. In contrast, we showed that EZH2
mRNA levels were elevated in naive CD4+ T cells from
lupus patients compared to those from healthy controls.
This discrepancy might arise from the different Tcell pop-
ulations that were studied.
The process of T cell entry into inflamed tissue
involves multiple steps, including morphologic changes
occurring in T cells, adhesion of the freely circulating cells
to the endothelium, and subsequent migration into the tis-
sue. In lupus, infiltration of Tcells into inflamed tissue has
been well documented (26,27). Increased endothelial cell
activation, represented by elevated expression of E-selectin,
vascular cell adhesion molecule 1, and intercellular adhe-
sion molecule 1, which leads to increased adhesiveness to
leukocytes has been reported in the skin of lupus patients
(28). In lymphocytes from lupus patients, increased levels of
lymphocyte function–associated antigen 1 and very late acti-
vation antigen 4 have also been reported (29). Li and col-
leagues reported that lupus Tcells displayed a higher ability
to adhere to hyaluronic acid–coated plates, and this was
mediated by the increased phosphorylation of ezrin, radixin,
and moesin and increased expression of CD44 (30). Our
findings identify JAM-A as a novel molecule involved in the
increased cell adhesion, and possibly tissue invasiveness, of
lupus CD4+Tcells.
JAM-A is a member of the immunoglobulin super-
gene family that has been identified at tight junctions
between endothelial cells and epithelial cells. It is also
expressed on some circulating cells, including lymphocytes
(31). JAM-A is engaged in a number of binding interac-
tions, including hemophilic interactions linking adjacent
endothelial and epithelial cells to stabilize intercellular
junctions, as well as heterophilic interactions with leuko-
cyte integrins or JAMs to facilitate leukocyte influx during
inflammation (32,33). The importance of JAM-A in
leukocyte–endothelial cell interactions has been high-
lighted in studies using JAM-A–deficient mice and neu-
tralizing antibodies to JAM-A (34–36). To our knowledge,
we are the first to report that the levels of JAM-A were
elevated in lupus CD4+ T cells, and to show that JAM-A
mediates increased Tcell adhesion to endothelial cells. In
other autoimmune diseases, dysregulated expression of
JAM-A has been reported (37). Decreased expression of
JAM-A was observed in scleroderma skin endothelial
cells, while increased expression of JAM-A was reported
in scleroderma fibroblasts, which mediated myeloid cell
retention on scleroderma skin (37). In peripheral blood
mononuclear cells isolated from rheumatoid arthritis
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patients, F11R was hypomethylated, and an up-regulation
of F11R was observed (38,39), similar to observations in
the current study.
In summary, our findings indicate a novel role of
EZH2 in Tcell adhesion, and a potentially pathogenic role
of EZH2 overexpression in lupus. Up-regulation of EZH2
in lupus CD4+ Tcells, possibly mediated by down-regula-
tion of miR-26a and miR-101, results in an increase in
H3K27me3 levels. EZH2 overexpression in T cells alters
the DNA methylome and highlights the involvement
of EZH2 in leukocyte adhesion and migration, via up-
regulation of JAM-A. We show that increased lupus CD4+
Tcell adhesion is mediated by JAM-A overexpression, and
that blockade of JAM-A or EZH2 can reduce the ability of
CD4+ Tcells to adhere to endothelial cells. These results
suggest that inhibition of JAM-A or EZH2 could be a
potential novel therapeutic approach in the management
of lupus.
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